share_log

康诺亚-B(02162.HK):CM313治疗成人原发免疫性血小板减少症(ITP)的探索性临床研究结果近日于《新英格兰医学杂志》发表

Conybio-B (02162.HK): The exploratory clinical study of CM313 for the treatment of primary immune thrombocytopenia (ITP) in adults was recently published in the New England Journal of Medicine.

Gelonghui Finance ·  Jun 19 20:17

On June 20th, Global Times reported that the team led by Zhang Lei from the Chinese Academy of Medical Sciences Hematology Research Institute published a research paper entitled 'A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia' in the New England Journal of Medicine. This is an investigator-initiated, single-arm, open, exploratory clinical study designed to evaluate the safety and preliminary efficacy of CM313 in adult primary immune thrombocytopenia patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment